Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.69 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 7/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | ESRRA | P11474 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304433 | 1.00 | RXRA (0.69) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL1619112 | 1.00 | RXRA (0.69) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL7462867 | 0.92 | RXRA (0.59) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL7462864 | 0.92 | RXRA (0.59) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL6450433 | 0.90 | RXRA (0.66) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL6450432 | 0.90 | RXRA (0.66) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL14492768 | 0.90 | RXRA (0.57) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5484611 | 0.90 | RXRA (0.57) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5484607 | 0.90 | RXRA (0.57) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5486526 | 0.89 | RXRA (0.61) | RXRASCN9APIM1PIM2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392326-B1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL JANSSEN PHARM (US) | 2009-09-09 | — | — | EP | claimed |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | BUSSOLARI JACQUELINE C | 2009-03-19 | — | — | US | claimed |
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1487446-A4 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-19 | — | — | EP | claimed |
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | claimed |
| US-6838442-B2 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-04 | — | — | US | claimed |
| EP-1487446-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego, Inc. (US) | 2004-12-22 | — | — | EP | claimed |
| EP-1392326-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | Ortho McNeil Pharmaceutical, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2004-02-19 | — | — | US | claimed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | claimed |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | BUSSOLARI JACQUELINE C (US) | 2003-10-16 | — | — | US | claimed |
| WO-2003075858-A2 | BICYCLIC HETEROCYCLES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | claimed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | claimed |
| WO-2002080935-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-10604541-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604541-B2 | Glucokinase activators and methods of using same | GCK, GCKR, GALK1 | RXRA 1949/4885SCN9A 1687/4885PIM1 2331/4885 |
| US-20040034004-A1 | Bicyclic heterocycles for the treatment of diabetes and other diseases | PC, CYP27A1, GPR119 | RXRA 1262/4885SCN9A 4099/4885PIM1 2592/4885 |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | GPR119, SLC2A4, SLC2A1 | RXRA 11/4885SCN9A 3138/4885PIM1 4727/4885 |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | GPR119, SLC2A4, SLC2A1 | RXRA 11/4885SCN9A 3138/4885PIM1 4727/4885 |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | RXRA 955/4885SCN9A 2999/4885PIM1 1292/4885 |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | GPR119, SLC2A4, SLC2A1 | RXRA 11/4885SCN9A 3138/4885PIM1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.